Central Serous Chorioretinopathy Clinical Trial
Official title:
Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy
Verified date | April 2018 |
Source | Peking University People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.
Status | Completed |
Enrollment | 23 |
Est. completion date | March 27, 2018 |
Est. primary completion date | December 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA - Presence of SRF and/or serous pigment epithelial detachment on OCT - Presence of abnormal dilated choroidal vasculature in ICGA Exclusion Criteria: - Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease - Any disease that may affect the quality of imaging (quality of OCTA images < 6), such as cataract, high myopia or nystagmus - History of ocular surgeries including retinal laser - Pregnancy - Any uncontrolled systemic disease - Any condition rendering patients intolerable to image acquisition |
Country | Name | City | State |
---|---|---|---|
China | People's Hospital of Peking University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital | National Natural Science Foundation of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with subretinal fluid resolution on OCT after PDT of two groups | 3 months | ||
Secondary | Number of patients with leakage point resolution on FFA after PDT of two groups | 3 months | ||
Secondary | Number of recurrent CSC after PDT of two groups | 3 months | ||
Secondary | BCVA (best corrected visual acuity) at every follow-up of two groups | 1 month, 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03692169 -
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
|
||
Not yet recruiting |
NCT02215330 -
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
|
Phase 2/Phase 3 | |
Completed |
NCT01990677 -
Eplerenone for the Treatment of Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01971190 -
Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT01710332 -
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
|
Phase 2 | |
Active, not recruiting |
NCT00403884 -
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
|
N/A | |
Recruiting |
NCT05570591 -
Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy
|
N/A | |
Recruiting |
NCT05589974 -
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
|
||
Completed |
NCT05104138 -
Eplerenone Versus PDT: Comparative Study by OCTA
|
||
Terminated |
NCT01982383 -
Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT01327170 -
Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
|
N/A | |
Completed |
NCT01019668 -
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
|
N/A | |
Recruiting |
NCT06346405 -
Central Serous Chorioretinopathy and Micropulse Laser Treatment
|
||
Recruiting |
NCT02141308 -
OCT in Rare Chorioretinal Diseases
|
||
Completed |
NCT01822561 -
Eplerenone for Central Serous Chorioretinopathy
|
Phase 2 | |
Completed |
NCT00802906 -
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
|
N/A | |
Withdrawn |
NCT05679180 -
Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE
|
N/A | |
Completed |
NCT05686421 -
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
|
N/A | |
Completed |
NCT03758963 -
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
|
N/A |